Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QLS 31905

Next Previous
X
Search
Drug Profile

QLS 31905

Alternative Names: anti-claudin 18.2/CD3 bispecific antibody; QLS-31905

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (IV, Injection)
  • 06 Jun 2024 Qilu Pharmaceutical plans a phase II trial for Solid tumours (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV, Infusion) in June 2024 (NCT06446388)
  • 18 Sep 2023 Qilu Pharmaceutical plans a phase Ib/II trial for Solid tumours (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV, Infusion) in October 2023 (NCT06041035)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top